You’re halfway out the door with one shoe on, keys in hand, when the light through the window suddenly feels hostile. The meeting will happen without you. Dinner plans may, too. Migraine does not just bring pain; it can take whole days off the calendar.
The old path was built from borrowed tools
For years, migraine prevention often began with medications originally designed for other conditions: blood pressure drugs, seizure medications, and antidepressants. Many still have a real role. Propranolol may make sense for some people with overlapping heart-related concerns. Amitriptyline may be considered when sleep is also a problem. Topiramate may help some patients.
But these options can come with tradeoffs: sleepiness, weight changes, brain fog, or pregnancy-related concerns. A CMAJ review reported low persistence with older oral preventives—26 to 29% at six months, and 17 to 20% at twelve months. Persistence is a clinical word, but the human meaning is simple: people stop when the treatment feels harder to live with than the migraine pattern.
What changed with the American Headache Society CGRP update
In March 2024, the American Headache Society said CGRP-targeting therapies can be considered a first-line option for migraine prevention. Not the only first choice. Not the best fit for everyone. But no longer something that should require several older medication failures first.
CGRP stands for calcitonin gene-related peptide, a signaling molecule involved in migraine pain pathways and blood vessel changes. During migraine attacks, CGRP levels can rise, and blocking that pathway has been associated with fewer migraine days for many patients.
That is the key shift in CGRP migraine medication: these treatments were designed around migraine biology rather than borrowed from unrelated conditions. The first CGRP monoclonal antibodies became available in 2018, and the AHS statement names options including erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, and atogepant. AHS educational materials say more than 150 new clinical and real-world studies supported the first-line option change.
Who might consider migraine preventive therapy?
A CMAJ review says prevention is commonly considered at four or more migraine headache days per month, or two days with substantial disability. That second part matters. Two attacks can be enough if they erase caregiving, school, work, or basic function.
Picture Maya. She has six migraine days a month—not daily, but enough to cancel plans, miss deadlines, dim lights, and lose confidence in her own schedule. Before her appointment, she tracks migraine days, disability days, rescue medication use, sleep changes, menstrual timing, and possible triggers for one month.
That record changes the visit. Instead of saying, “My migraines are bad,” she can say, “I had six migraine days, missed two work deadlines, used acute medication on five days, and lost one weekend.” That gives a clinician something concrete to work with.
The practical questions: cost, side effects, and fit
Targeted does not mean risk-free. CGRP works throughout the body, so the conversation should include constipation, blood pressure, vascular history, pregnancy planning, and cost.
CGRP monoclonal antibodies are usually given by injection or infusion on schedules that vary by medication. Preventive gepants, including rimegepant and atogepant, are oral CGRP-pathway options. Some people prefer less frequent dosing; others would rather take a pill. Convenience matters because prevention only helps when it fits your life.
Access matters, too. Step therapy has often required people to prove they struggled on older drugs before insurance would consider migraine-specific prevention. Insurance may still ask for that history. If so, a clinician may be able to reference the 2024 AHS position statement in an appeal. Consider asking about prior authorization, copay programs, documentation, formulary alternatives, and what happens if the first request is denied.
This content is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor or a qualified healthcare provider before making changes to your health routine.
A better appointment starts with better language
One useful phrase is: “I know older medicines can help, but can we discuss CGRP prevention as a first-line option for me?”
Then let the conversation breathe. Ask what benefits would count as success, what side effects to watch for, how long to try a preventive before judging it, and what the backup plan is.
Your personal goal may not be “zero attacks.” It may be fewer migraine days, fewer severe days, less acute medication, or a faster return to normal activity. Maybe success means finishing a shift, making school pickup, or staying through dessert.
The current AHS answer is that CGRP migraine prevention can be considered without requiring several older medication failures first. That does not remove every barrier, but it changes the conversation from earning access to choosing care.
Before your next appointment, write down three things: your migraine days, what migraine costs you, and which tradeoffs you are unwilling to make. Migraine already takes enough. Prevention should begin with evidence, honesty, and a plan built around your actual life.
